Skip to main content

The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma.

Publication ,  Journal Article
Broski, SM; Hunt, CH; Johnson, GB; Subramaniam, RM; Peller, PJ
Published in: J Nucl Med
August 2012

UNLABELLED: The purpose of this study was to evaluate the clinical utility of (18)F-FDG PET/CT in esthesioneuroblastoma staging and restaging and quantify the additional benefit of PET/CT to conventional imaging. METHODS: A retrospective review was performed with institutional review board approval for patients with a diagnosis of esthesioneuroblastoma who underwent PET/CT from 2000 to 2010. PET/CT results were retrospectively reviewed by 2 radiologists who were unaware of the clinical and imaging data. Positive imaging findings were classified into 3 categories: local disease, cervical nodal spread, and distant metastasis. All conventional imaging performed in the 6 mo preceding PET/CT, and the medical records, were reviewed to determine the potential added value. RESULTS: Twenty-eight patients (mean age, 52.3 ± 10 y; range, 23-81 y) were identified who underwent a total of 77 PET/CT examinations. Maximum standardized uptake value (SUVmax) was 8.68 ± 4.75 (range, 3.6-23.3) for the primary tumor and 8.57 ± 6.46 (range, 1.9-27.2) for the metastatic site. There was no clear association between primary tumor SUVmax and tumor grade (P = 0.30). Compared with conventional imaging, PET/CT changed disease stage or altered clinical management in 11 (39%) of 28 esthesioneuroblastoma patients. Of these, 10 (36%) of 28 were upstaged on the basis of their PET/CT studies. Cervical nodal metastases were found in 5 (18%) of 28, local recurrence in 2 (7%) of 28, cervical nodal and distant metastases in 2 (7%) of 28, and distant metastases in 1 (4%) of 28. One patient (4%) was downstaged after negative findings on PET/CT. CONCLUSION: PET/CT is a useful adjunct to conventional imaging in the initial staging and restaging of esthesioneuroblastoma by detecting nodal and distant metastatic disease not demonstrated by conventional imaging and identifying local recurrence hidden by treatment changes on conventional imaging.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Nucl Med

DOI

EISSN

1535-5667

Publication Date

August 2012

Volume

53

Issue

8

Start / End Page

1200 / 1206

Location

United States

Related Subject Headings

  • Young Adult
  • Tomography, X-Ray Computed
  • Retrospective Studies
  • Recurrence
  • Positron-Emission Tomography
  • Nuclear Medicine & Medical Imaging
  • Nose Neoplasms
  • Neoplasm Staging
  • Nasal Cavity
  • Multimodal Imaging
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Broski, S. M., Hunt, C. H., Johnson, G. B., Subramaniam, R. M., & Peller, P. J. (2012). The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma. J Nucl Med, 53(8), 1200–1206. https://doi.org/10.2967/jnumed.112.102897
Broski, Stephen M., Christopher H. Hunt, Geoffrey B. Johnson, Ratham M. Subramaniam, and Patrick J. Peller. “The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma.J Nucl Med 53, no. 8 (August 2012): 1200–1206. https://doi.org/10.2967/jnumed.112.102897.
Broski SM, Hunt CH, Johnson GB, Subramaniam RM, Peller PJ. The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma. J Nucl Med. 2012 Aug;53(8):1200–6.
Broski, Stephen M., et al. “The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma.J Nucl Med, vol. 53, no. 8, Aug. 2012, pp. 1200–06. Pubmed, doi:10.2967/jnumed.112.102897.
Broski SM, Hunt CH, Johnson GB, Subramaniam RM, Peller PJ. The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma. J Nucl Med. 2012 Aug;53(8):1200–1206.

Published In

J Nucl Med

DOI

EISSN

1535-5667

Publication Date

August 2012

Volume

53

Issue

8

Start / End Page

1200 / 1206

Location

United States

Related Subject Headings

  • Young Adult
  • Tomography, X-Ray Computed
  • Retrospective Studies
  • Recurrence
  • Positron-Emission Tomography
  • Nuclear Medicine & Medical Imaging
  • Nose Neoplasms
  • Neoplasm Staging
  • Nasal Cavity
  • Multimodal Imaging